YOLFTbeta
Diamyd Medical AB (publ)

Diamyd Medical AB (publ)

DMYD-B · ST · Healthcare / Biotechnology

0.921SEK-0.02 (-2.33%)

Price History

Full chart

Market Stats

Previous Close0.943
Open0.913
Day Range0.903 – 0.948
52-Week Range0.896 – 17.88
Volume490.30K
Market Cap157.46M
P/E (TTM)0.00
Forward P/E0.00
EPS-2.00
Dividend Yield0.00%
Beta2.29
50-Day Avg1.03
200-Day Avg5.53

About

Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. It has a research and development collaboration agreement with Juvenile Diabetes Research Foundation to develop DIAGNODE-3 Phase 3 trial in type 1 diabetes. Diamyd Medical AB (publ) was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. The company was founded in 1984 and is headquartered in Stockholm, Sweden.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Anders Essen-Möller M.Sc.
  • Employees44
  • HeadquartersKungsgatan 29, Stockholm, Sweden, 111 56, Sweden
  • Websitehttps://www.diamyd.com

Leadership

  • Mr. Anders Essen-Möller M.Sc.Chief Executive Officer · b. 1941
  • Mr. Mathias SkalmstadChief Financial Officer · b. 1973
  • Ms. Martina WidmanChief Operating Officer · b. 1981
  • Mr. Anton LindqvistChief Scientific Officer · b. 1980
  • Sofia MayansHead of Manufacturing Site · b. 1976

Financials

Income Statement

Currency: SEK2010-08-312011-08-312012-08-312013-08-312014-08-312015-08-312016-08-312017-08-312018-08-312019-08-312020-08-312021-08-312022-08-312023-08-312024-08-312025-08-31
Total Revenue113.03M280.75M514.00K100.00K443.00K513.00K757.00K922.00K726.00K1.57M341.00K253.00K454.00K546.00K130.00K130.00K
Growth (%)-+148.39%-99.82%-80.54%+343.00%+15.80%+47.56%+21.80%-21.26%+115.98%-78.25%-25.81%+79.45%+20.26%-76.19%0.00%
Cost of Revenue26.00K7.00K877.00K756.00K1.26M1.35M911.00K1.74M2.11M1.69M4.49M2.50M4.40M3.63M3.71M3.83M
Gross Profit113.00M280.75M-363.00K-656.00K-819.00K-838.00K-154.00K-818.00K-1.38M-125.00K-4.15M-2.25M-3.95M-3.09M-3.58M-3.71M
Gross Margin99.98%100.00%-70.62%-656.00%-184.88%-163.35%-20.34%-88.72%-190.50%-7.97%-1216.13%-888.54%-869.82%-565.57%-2753.85%-2850.00%
Operating Expense115.97M169.41M16.45M12.38M15.91M20.73M31.91M24.70M42.65M36.44M-13.89M83.63M114.23M117.72M142.99M179.53M
Operating Income-2.96M111.34M-16.81M-13.03M-16.73M-21.57M-32.06M-25.52M-44.04M-36.57M9.74M-85.88M-118.18M-120.81M-146.57M-183.24M
Operating Margin-2.62%39.66%-3270.23%-13032.00%-3776.98%-4204.29%-4235.01%-2767.90%-6065.56%-2332.21%2856.01%-33944.66%-26029.96%-22125.64%-112743.85%-140950.77%
EBITDA-2.74M111.77M-16.62M-12.88M-16.62M-21.54M-31.90M-25.38M-43.62M-36.35M10.39M61.28M-98.88M-111.20M-140.85M-176.73M
EBITDA Margin-2.42%39.81%-3234.24%-12877.00%-3752.60%-4199.22%-4214.27%-2752.93%-6008.26%-2318.18%3046.33%24221.34%-21779.74%-20366.48%-108346.92%-135946.15%
Net Income-332.00K102.57M-16.24M-12.63M-16.03M-21.40M-32.01M-25.55M-43.95M-36.73M9.71M60.05M-103.52M-116.07M-151.85M-169.78M
Net Income Margin-0.29%36.53%-3159.92%-12633.00%-3619.41%-4170.96%-4228.27%-2771.69%-6054.13%-2342.54%2847.21%23733.60%-22801.10%-21258.79%-116807.69%-130597.69%
R&D80.84M95.98M25.05M3.52M5.46M9.69M6.22M12.87M29.12M22.36M13.81M56.86M75.57M69.91M96.48M119.50M
R&D as % of Total Revenue71.53%34.19%4873.15%3519.00%1233.63%1888.11%821.66%1395.99%4010.74%1425.96%4049.85%22474.31%16644.71%12803.85%74218.46%91926.15%
Interest Expense09.91M0000067.00K202.00K121.00K530.00K453.00K253.00K3.00K8.00K3.70M
Interest Expense % of Total Revenue0.00%3.53%0.00%0.00%0.00%0.00%0.00%7.27%27.82%7.72%155.43%179.05%55.73%0.55%6.15%2847.69%

Balance Sheet

Currency: SEK2010-08-312011-08-312012-08-312013-08-312014-08-312015-08-312016-08-312017-08-312018-08-312019-08-312020-08-312021-08-312022-08-312023-08-312024-08-312025-08-31
Total Assets569.19M519.60M421.74M67.82M51.02M46.65M37.78M98.65M54.98M74.20M89.76M201.44M236.52M205.81M217.04M352.64M
Total Liabilities254.41M58.63M12.16M7.52M6.86M7.12M8.52M11.98M11.97M11.42M17.28M12.18M22.14M36.41M71.12M72.64M
Total Equity314.78M460.97M409.58M60.29M44.16M39.52M29.26M86.67M43.01M62.78M72.49M189.26M214.38M169.40M145.92M280.00M
Cash501.33M157.78M164.34M65.52M24.71M16.73M26.40M55.69M14.08M36.70M58.37M139.38M119.76M127.53M112.76M277.19M
Total Debt-------------15.87M30.67M45.04M
Net Debt-501.33M-157.78M-164.34M-65.52M-24.71M-16.73M-26.40M-55.69M-14.08M-36.70M-58.37M-139.38M-119.76M-111.67M-82.09M-277.19M

Cash Flow

Currency: SEK2010-08-312011-08-312012-08-312013-08-312014-08-312015-08-312016-08-312017-08-312018-08-312019-08-312020-08-312021-08-312022-08-312023-08-312024-08-312025-08-31
Operating Cash Flow225.77M-94.03M-55.99M-13.71M-16.69M-18.31M-17.75M-25.81M-41.56M-39.19M16.88M-109.47M-93.22M-110.96M-129.18M-169.68M
Investing Cash Flow-700.00K-279.79M61.90M36.88M-24.14M-4.44M5.67M-27.89M-352.00K5.35M4.82M132.53M-76.72M28.40M-27.99M17.17M
Financing Cash Flow238.86M37.56M288.00K20.39M-95.00K14.96M21.75M82.96M298.00K56.38M-1.00K56.72M142.16M86.54M142.28M316.32M
Capital Expenditure700.00K1.93M93.00K0130.00K400.00K0347.00K347.00K1.98M1.98M4.22M34.65M11.44M8.03M10.05M
Free Cash Flow225.07M-95.95M-56.08M-13.71M-16.82M-18.71M-17.75M-25.81M-41.91M-39.19M14.90M-113.69M-127.87M-122.40M-137.21M-179.73M
FCF to OCF99.69%102.05%100.17%100.00%100.78%102.18%100.00%100.00%100.83%100.00%88.28%103.86%137.17%110.31%106.21%105.92%

Earnings

Report DateMay 31, 2013Aug 31, 2013Nov 30, 2013Feb 28, 2014May 31, 2014Aug 31, 2014Nov 30, 2014Feb 28, 2015May 31, 2015Aug 31, 2015Nov 30, 2015Feb 29, 2016May 31, 2016Aug 31, 2016Nov 30, 2016Apr 5, 2017Jun 28, 2017Nov 9, 2017Jan 24, 2018Mar 28, 2018Aug 1, 2018Oct 3, 2018Jan 23, 2019Mar 27, 2019Jun 26, 2019Oct 2, 2019Jan 22, 2020Mar 25, 2020Jun 24, 2020Oct 7, 2020Jan 20, 2021Mar 25, 2021Jun 23, 2021Oct 13, 2021Jan 26, 2022Mar 30, 2022Jun 22, 2022Oct 5, 2022Jan 25, 2023Apr 5, 2023Jun 28, 2023Oct 11, 2023Jan 24, 2024Mar 27, 2024Jun 26, 2024Oct 9, 2024Jan 22, 2025Apr 9, 2025May 31, 2025Aug 31, 2025Nov 30, 2025Feb 28, 2026May 31, 2026
EPS Estimate---------------------------0.00------------------0.00------
EPS Actual-0.31-0.20-0.19-0.17-0.14-0.13-0.23-0.16-0.27-0.15-0.15-0.18-0.60-0.14-0.13-0.32-0.25-0.17-0.19-0.16-0.22-0.21-0.15-0.16-0.12-0.14-0.100.54-0.10-0.191.520.22-0.47-0.38-0.52-0.12-0.22-0.48-0.43-0.32-0.27-0.26-0.37-0.31-0.41-0.50-0.35-0.43-0.41-0.33-0.36-0.46-0.84
Surprise-----------------------------------------------------
Timing---------------------Pre-marketPre-marketPre-marketPre-marketPre-marketPre-market-After-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-market-----

Key Statistics & Ratios

Market Cap157.46M
Enterprise Value57.94M
Trailing P/E0.00
Forward P/E0.00
Price / Sales364.50
Price / Book0.62
EPS-2.00
Book Value1.67
Revenue (TTM)432.00K
Gross Profit (TTM)-2.97M
EBITDA-280.63M
Profit Margin0.00%
Operating Margin-181711.43%
Return on Equity-97.13%
Return on Assets-44.56%
Shares Outstanding151.48M
Shares Float132.05M
Beta2.29
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%